-The Telegraph Regulators in several European countries are suspending marketing approval for 25 generic drugs because of concerns over the quality of data from human studies conducted by an Indian contract research company, a French medical safety agency said on Friday. Drug regulators in Belgium, France, Germany and Luxembourg have decided to suspend the marketing authorisation for the generic drugs after they discovered "irregularities" in documents relating to human studies conducted by...

-The Hindustan Times The editor, a liberal man, is taken aback by my question. "I don't hire people on the basis of their caste but their ability," he informs me when I ask how many Dalits he has in his newsroom. Nearly 70 years after Independence, my question should have been irrelevant. But a caste survey by the National Council of Applied Economic Research (NCAER) and the University of Maryland, United States,...

-Down to Earth Government sidelines its committee of experts to set up new panel to review India's intellectual property rights policy The politics of protecting intellectual property rights (IPR) is becoming more curiouswith the commerce ministry setting up a think tank to draft a national IPR policy while sidelining a committee of experts it had set up earlier. Annoyed academics who were asked to help formulate the policy in July this year...

-The Hindustan Times According to Nabanna sources, a rough average of working days created under MGNREGA in Bengal during the last three years shows that the state ranks a lowly16th among all states on this count. On the basis of the same average during the last three years in terms of working days created during the same period, the figure for Bengal is much lower than the national average. During the period...

-The Times of India NEW DELHI: The drug price regulator has mandated companies to seek its approval for every new medicine, including combinations of existing ones, to ensure that consumers are not overcharged. According to the National Pharmaceutical Pricing Authority (NPPA) all innovative launches like new combinations of price-controlled medicines as well as those with changed strengths and dosages will be treated as 'new medicines'. The move is aimed at spanning the...